Aminex Therapeutics Initiates Phase 1b/2 Trial of Novel Polyamine-Targeting Cancer Therapy AMXT 1501 Plus DFMO
核心洞察
Aminex Therapeutics (搜索) has launched a Phase 1b/2 clinical trial evaluating AMXT 1501 combined with DFMO in patients with breast cancer or metastatic melanoma.
The novel combination therapy targets polyamine metabolism, a pathway essential for tumor growth and immune system suppression.
The multicenter trial will assess safety, tolerability, and preliminary efficacy in patients with ER+ HER2- breast cancer and metastatic melanoma who have progressed after prior therapies.
Aminex Therapeutics (搜索) has activated multiple sites for a Phase 1b/2 clinical trial of its investigational cancer treatment AMXT 1501 in combination with difluoromethylornithine (DFMO) for patients with breast cancer or metastatic melanoma. The Seattle-based clinical-stage biotechnology company announced the initiation of this multicenter, open-label trial on February 4, 2026.
Novel Mechanism Targets Essential Tumor Pathway
The combination therapy represents a novel approach that attacks polyamine production, which tumors require to proliferate and suppress the immune system. AMXT 1501 is a polyamine transport inhibitor designed to block the uptake of polyamines essential for tumor growth and survival, while DFMO is an established inhibitor of polyamine biosynthesis. Together, the combination aims to comprehensively inhibit polyamine metabolism and tumor growth.
"This trial builds on our foundation of pre- and early clinical data demonstrating the potential of AMXT 1501 plus DFMO to block the polyamine metabolism—a pathway that drives tumor growth and suppresses immune responses," said Mark Burns, PhD, Chief Scientific Officer and President of Aminex.
Trial Design and Patient Population
The multicenter trial (NCT07287917) will evaluate the safety, tolerability and preliminary efficacy of oral AMXT 1501 in combination with oral DFMO together with standard of care. The study targets two specific patient populations: patients with metastatic melanoma and pre- and post-menopausal women with ER+ HER2- breast cancer who have progressed after prior therapies. The trial design includes both safety and dose expansion cohorts.
Expanding Pediatric Oncology Program
Beyond the adult cancer trial, Aminex is partnering with The Beat Childhood Cancer Consortium (搜索) at Penn State College of Medicine (搜索) on a randomized Phase 1/2 clinical trial of AMXT 1501 plus DFMO in pediatric patients. This pediatric study (NCT06465199) encompasses six rare childhood cancers: neuroblastoma, diffuse intrinsic pontine glioma, atypical teratoid rhabdoid tumor, embryonal tumor with multilayer rosettes, ewing sarcoma, and osteosarcoma.
The company recently received Orphan Drug Designation from the FDA for AMXT 1501 plus DFMO for the treatment of patients with neuroblastoma, highlighting the regulatory recognition of this approach for rare pediatric cancers.
Clinical Significance for Advanced Cancer Patients
"Initiating this study is an important milestone for Aminex and for patients facing advanced cancers with limited treatment options," Burns noted. The company is advancing this program in collaboration with leading investigators and pediatric oncologists, targeting eight tumor types total across its clinical development pipeline.
The polyamine metabolism pathway represents a potentially significant therapeutic target, as it plays a dual role in both driving tumor growth and suppressing immune responses. This mechanism of action could offer new treatment options for patients with limited therapeutic alternatives in both adult and pediatric oncology settings.